Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Orion Corporation, Orion Pharma
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07563738CT.gov A 2-part Phase 1/2 Open-label Trial on ODM-212 | — | Recruiting | — | — | — |
NCT06941857CT.gov NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | — | Recruiting | — | — | — |
NCT05721846CT.gov Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05076760CT.gov MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05116917CT.gov Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. | — | Terminated | — | — | — |
NCT04925284CT.gov Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | — | Completed | — | — | — |
NCT04731467CT.gov A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | — | Completed | — | — | — |
NCT04477343CT.gov A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | — | Recruiting | — | — | — |
NCT04612530CT.gov PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer | — | Unknown | — | — | — |
Show 18 more trialsShow fewer
NCT03519308CT.gov A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer | — | Terminated | — | — | — |
NCT04117087CT.gov Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04396821CT.gov A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04361162CT.gov Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04258150CT.gov Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer | — | Terminated | — | — | — |
NCT03953235CT.gov A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | — | Completed | — | — | — |
NCT03829436CT.gov TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | — | Completed | — | — | — |
NCT03599362CT.gov Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer | — | Terminated | — | — | — |
NCT03161379CT.gov GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer | — | Completed | — | — | — |
NCT03190265CT.gov Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer | — | Completed | — | — | — |
NCT03250273CT.gov A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | — | Completed | — | — | — |
NCT03184870CT.gov A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03104439CT.gov Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT02581215CT.gov Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT02791334CT.gov A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | — | Completed | — | — | — |
NCT02451982CT.gov Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | — | Active Not Recruiting | — | — | — |
NCT02526017CT.gov Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers | — | Completed | — | — | — |
NCT02423954CT.gov Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Orion Corporation, Orion Pharma | P2 | B · 63 |
| Tinzaparin | Helsinki University Central Hospital | P4 | BBB |
| Oxaliplatin | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | BB |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Capecitabine | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Irinotecan | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Triglycerides,Medium Chain | Wei Zhou | P4 | BB |
| Desflurane | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | P4 | BB |
+42 more in the Pancreatic Neoplasm cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/nivolumab-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →